Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > INTELLECTUAL PROPERTY ATTORNEY, DR. PENG CHEN, JOINS RIMON AS PARTNER IN SAN DIEGO
    Top Stories

    INTELLECTUAL PROPERTY ATTORNEY, DR. PENG CHEN, JOINS RIMON AS PARTNER IN SAN DIEGO

    Published by Gbaf News

    Posted on March 17, 2018

    7 min read

    Last updated: January 21, 2026

    An informative graphic illustrating the link between Novo Nordisk's Ozempic and the increased risk of NAION, a rare eye disease. This image supports the article discussing recent studies and regulatory scrutiny.
    Graphic depicting Novo Nordisk's Ozempic diabetes drug and NAION eye disease risk - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Rimon Law has added Dr. Peng Chen as a partner in the firm’s Litigation and Intellectual Property (IP) groups. While Dr. Chen’s practice is global, he will be based out of San Diego.

    Dr. Chen joins Rimon from Morrison &Foerester LLP where he was a Partner.

    Dr. Chen has been ranked in the fields of biotechnology law, patent law and patent litigation 2009-2018 by Best Lawyers. In 2018, Dr. Chen has been selected as a “Lawyer of the Year” in Patent Law in San Diego by Best Lawyers.  Dr. Chen has also been ranked as a regional expert on China intellectual property by Chambers Global.

    Dr. Chen’s practice focuses on patent prosecution and strategic counseling, and he also is experienced in the areas of patent litigation, inter parties review, reexamination, interference, opposition, and licensing. He leads his biotechnology, pharmaceutical, and diagnostics clients through the technical and legal challenges involved in developing and protecting their critical IP assets.

    At Rimon, Dr. Chen will be joining a strong IP team of Partners across the U.S. representing clients all over the globe. The IP team also works closely with the Corporate, Tax, Private Client and Litigation teams to ensure that our clients benefit from full-spectrum representation. Because of Rimon’s decentralized business model, Dr. Chen will be able to customize his service to each client to provide an optimal experience. ‘

    “Life Science has been a booming part of the legal industry, as the pharmaceutical and biotech worlds continue to expand and needs top notch representation to handle the very challenging intellectual property issues.  Peng is at the very cutting edge of the biotech industry and his expertise will strengthen our biotech team. We are very glad to welcome Peng to Rimon,” said Michael Moradzadeh, CEO of Rimon.

    Dr. Chen will be adding to Rimon’s Life Science practice group, which includes James Chapman, Zheng Liu, Mark Mirkin, Dennis Raglin, and Frank Vargas. Dr. Chen also adds to an esteemed list of Patent Prosecutors at Rimon, which includes Marc Kaufman, Letao Qin and Robert Lee.

    “I am very excited to join Rimon Law because in my view, Rimon offers an optimal structure for providing top quality client service in a cost-effective manner.  I am also very impressed by Rimon’s expertise in many crucial practice areas, such as corporate and licensing, and Rimon’s international reach including the rapidly growing China practice,” said Dr. Chen.

    Dr. Chen is also going to add momentum to Rimon’s growing China practice along with Rimon Partners James Chapman, Letao Qin, Ajay Whittemore, Marc Kaufman, Zheng Liu, Yaacov Silberman, Juan Zuniga, Robert Q. Lee, Matthew Poppe, Chris Terry and Fred Chang.

    Dr. Chen earned his B.S. from Beijing Normal University in 1986, his Ph.D. from the John Hopkins University School of Medicine in 1993 and a J.D. in 1997 from Columbia Law School. He conducted his post-doctoral fellowship at Yale University School of Medicine and was a Harlan Fiske Stone Scholar while in law school.

    Rimon has 17 offices across three continents. The firm is widely known as being at the vanguard of legal innovation. The firm has been repeatedly recognized by the Financial Times as one of North America’s most innovative law firms. The firm’s managing partners were both named ‘Legal Rebels’ by the American Bar Association’s ABA Journal and have spoken on innovations in the practice of law at Harvard and Stanford Law Schools. Rimon and its lawyers have also received numerous awards for excellence, including from Best Lawyers and Chambers.

    Rimon Law has added Dr. Peng Chen as a partner in the firm’s Litigation and Intellectual Property (IP) groups. While Dr. Chen’s practice is global, he will be based out of San Diego.

    Dr. Chen joins Rimon from Morrison &Foerester LLP where he was a Partner.

    Dr. Chen has been ranked in the fields of biotechnology law, patent law and patent litigation 2009-2018 by Best Lawyers. In 2018, Dr. Chen has been selected as a “Lawyer of the Year” in Patent Law in San Diego by Best Lawyers.  Dr. Chen has also been ranked as a regional expert on China intellectual property by Chambers Global.

    Dr. Chen’s practice focuses on patent prosecution and strategic counseling, and he also is experienced in the areas of patent litigation, inter parties review, reexamination, interference, opposition, and licensing. He leads his biotechnology, pharmaceutical, and diagnostics clients through the technical and legal challenges involved in developing and protecting their critical IP assets.

    At Rimon, Dr. Chen will be joining a strong IP team of Partners across the U.S. representing clients all over the globe. The IP team also works closely with the Corporate, Tax, Private Client and Litigation teams to ensure that our clients benefit from full-spectrum representation. Because of Rimon’s decentralized business model, Dr. Chen will be able to customize his service to each client to provide an optimal experience. ‘

    “Life Science has been a booming part of the legal industry, as the pharmaceutical and biotech worlds continue to expand and needs top notch representation to handle the very challenging intellectual property issues.  Peng is at the very cutting edge of the biotech industry and his expertise will strengthen our biotech team. We are very glad to welcome Peng to Rimon,” said Michael Moradzadeh, CEO of Rimon.

    Dr. Chen will be adding to Rimon’s Life Science practice group, which includes James Chapman, Zheng Liu, Mark Mirkin, Dennis Raglin, and Frank Vargas. Dr. Chen also adds to an esteemed list of Patent Prosecutors at Rimon, which includes Marc Kaufman, Letao Qin and Robert Lee.

    “I am very excited to join Rimon Law because in my view, Rimon offers an optimal structure for providing top quality client service in a cost-effective manner.  I am also very impressed by Rimon’s expertise in many crucial practice areas, such as corporate and licensing, and Rimon’s international reach including the rapidly growing China practice,” said Dr. Chen.

    Dr. Chen is also going to add momentum to Rimon’s growing China practice along with Rimon Partners James Chapman, Letao Qin, Ajay Whittemore, Marc Kaufman, Zheng Liu, Yaacov Silberman, Juan Zuniga, Robert Q. Lee, Matthew Poppe, Chris Terry and Fred Chang.

    Dr. Chen earned his B.S. from Beijing Normal University in 1986, his Ph.D. from the John Hopkins University School of Medicine in 1993 and a J.D. in 1997 from Columbia Law School. He conducted his post-doctoral fellowship at Yale University School of Medicine and was a Harlan Fiske Stone Scholar while in law school.

    Rimon has 17 offices across three continents. The firm is widely known as being at the vanguard of legal innovation. The firm has been repeatedly recognized by the Financial Times as one of North America’s most innovative law firms. The firm’s managing partners were both named ‘Legal Rebels’ by the American Bar Association’s ABA Journal and have spoken on innovations in the practice of law at Harvard and Stanford Law Schools. Rimon and its lawyers have also received numerous awards for excellence, including from Best Lawyers and Chambers.

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostYOLT TO BRING ON UP TO 300 OPEN BANKING USERS PER DAY FROM THE RBS GROUP
    Next Top Stories PostMYPINPAD AND INGENICO PARTNER TO PILOT ‘PIN ON MOBILE’ TECHNOLOGY FOR INNOVATIVE CARD PAYMENTS